Originally published In Press as doi:10.1074/jbc.M110270200 on February 11, 2002
J. Biol. Chem., Vol. 277, Issue 17, 14443-14450, April 26, 2002
Identification of Sterol-independent Regulatory Elements in the
Human ATP-binding Cassette Transporter A1 Promoter
ROLE OF Sp1/3, E-BOX BINDING FACTORS, AND AN ONCOSTATIN
M-RESPONSIVE ELEMENT*
Thomas
Langmann
,
Mustafa
Porsch-Özcürümez
,
Susanne
Heimerl,
Mario
Probst,
Christoph
Moehle,
Mohammed
Taher,
Hana
Borsukova,
Danuta
Kielar,
Wolfgang E.
Kaminski,
Elke
Dittrich-Wengenroth§, and
Gerd
Schmitz¶
From the Institute for Clinical Chemistry, University of
Regensburg, 93042 Regensburg, Germany, and the § Pharma
Research Center, Bayer AG, Aprather Wey 18a, D-42096 Wuppertal,
Germany
Received for publication, October 25, 2001, and in revised form, January 23, 2002
 |
ABSTRACT |
The ATP-binding cassette transporter
A1 (ABCA1) shows a differentiation-, cAMP-, and
sterol-dependent up-regulation in human monocytes. As part
of an ongoing study, we investigated the proximal promoter regions that
are highly conserved between the human and murine ABCA1 genes. Using
reporter gene assays, we show here that a TATA box 24 bp upstream of
the transcription initiation site is essential for promoter activity in
RAW 264.7 and HepG2 cells, whereas further enhancement of
transcriptional activity is mediated by the
175 bp promoter region.
Gel shift assays revealed in vitro binding of Sp1 to a
91
GnC motif as well as binding of Sp1 and Sp3 to a
157 GnC promoter
region. In co-transfection experiments using Drosophila S2
cells, we demonstrate that Sp3 competes with Sp1 for binding to the
157 GnC motif and acts as a repressor. On the other hand,
overexpression of Sp1 increased ABCA1 mRNA expression in HeLa cells
and enhanced cellular cholesterol and phospholipid efflux in RAW 246.7 macrophages. We also show here that the conserved E-box at position
140 binds upstream stimulatory factors 1 and 2 and hepatic nuclear
factor 1
and that mutagenesis of the E-box enhanced
constitutive ABCA1 expression in RAW 264.7 cells, implying a role for
this element in silencing ABCA1 expression. Besides the functional
importance for basal gene expression, we have identified that the core
promoter region (
175 to +224) is also responsible for the induction
of ABCA1 by the cytokine oncostatin M, resulting in a rapid increase in
ABCA1 mRNA levels in HepG2 cells. Interestingly, this oncostatin
M-induced expression is not dependent on the currently known sequence
motifs in the ABCA1 promoter. In conclusion, a functional complex of
cis-elements within the proximal human ABCA1 promoter associated with
the transcription factors Sp1/3, upstream stimulatory factors 1 and 2, and hepatic nuclear factor 1
has been characterized, which allows a
subtle tissue-specific regulation of ABCA1 gene expression.
 |
INTRODUCTION |
The ATP-binding cassette transporter A1
(ABCA1)1 was recently
identified as a key regulator of cellular cholesterol efflux (1-3).
Mutations of the ABCA1 gene are the causative defect in genetic HDL
deficiency syndromes, and affected subjects have a defect in cellular
cholesterol removal, which results in the almost complete absence of
plasma HDL cholesterol (4). Cells lacking functional ABCA1 are
characterized by structural and functional abnormalities including
impaired raft/caveolar processing and Golgi-dependent
lipid export processes due to impaired vesicular budding and excess
lipid storage in the trans-Golgi network (5).
Expression of ABCA1 gene transcription is up-regulated in human
monocytes during phagocytic differentiation, and its expression is
further increased by loading with modified lipoproteins (6) or cAMP
treatment (7, 8). In addition, peroxisome-proliferator-activated receptor (PPAR) agonists and interferon-
modulate ABCA1 expression (9, 10). Following earlier papers describing the ABCA1 promoter sequence (11, 12) (for an update see Refs. 13 and 14), recent reports
have mainly focused on the interaction between LXR/RXR and a
corresponding DR4 element in the proximal ABCA1 promoter region (15,
16). Interestingly, an alternative promoter in the first intron has
been recently identified and shown to mediate liver-specific
LXR/RXR-dependent ABCA1 expression in two different
transgenic mouse models (17-19). LXR/RXR-responsive elements trigger
retinoic acid and oxysterol-dependent activation of the ABCA1 promoter and thereby confer the observed induction of ABCA1 during lipid loading of macrophages. The most likely endogenous ligand
for LXR
and LXR
is 27-hydroxycholesterol, since CYP27-deficient cells are not able to up-regulate ABCA1 in response to sterols and
since overexpression of CYP27 activates LXR/RXR (20). Also, the earlier
described LXR ligands 20(S)-hydroxycholesterol,
22(R)-hydroxycholesterol, and
24(S),25-epoxycholesterol are not present in
cholesterol-loaded macrophages, rendering them unlikely to be
natural ligands of LXR (20).
Only little functional information is available on how constitutive and
tissue-specific expression of ABCA1 is maintained. In a recent work
from our group, the transcriptional repressor ZNF202 has been
identified as a critical modulator of ABCA1 and ATP-binding cassette
transporter G1 gene expression (21). Following these studies and on the
basis of a comparison between human and murine ABCA1 proximal promoter
regions, we investigated in detail the functional properties of two
conserved GnC motifs that bind the zinc finger proteins Sp1 and Sp3
within the core promoter sequence. We show that both sites are of
functional relevance for constitutive ABCA1 gene expression in
macrophage and liver cells. Furthermore, an E-box between the two GnC
motifs acts as a silencer and binds the basic helix-loop-helix proteins
upstream stimulatory factor 1 (USF1) and USF2 and the homeodomain-type protein hepatic nuclear factor 1
(HNF-1
) in in vitro
binding assays. Our data also for the first time describe the induction of the ABCA1 promoter by oncostatin M and localize the responsive element within the
175/+229 bp core promoter region.
 |
EXPERIMENTAL PROCEDURES |
Reporter and Expression Plasmid Constructs--
Primers for the
amplification of the putative ABCA1 promoter sequence were based on a
genomic sequence provided by the Whitehead Institute/MIT Center for
Genome Research (Cambridge, MA) (accession number AC012230). The human
BAC clone RP11-1M10, which contains the genomic ABCA1 5' region, was
provided by the Resource Center of the German Human Genome Project
(RZPD) and served as a template for the amplification of the promoter
sequence with the High Fidelity PCR system (Roche Diagnostics).
Reporter constructs of the ABCA1 promoter sequence were cloned by
ligation of PCR fragments into the BglII and NheI
restriction sites of the pGL3-basic vector. Six inserts of increasing
length were obtained by PCR. A promoterless pGL3-basic vector served as
negative control, whereas the pGL3-control vector, which contains the
SV40 early promoter, was used as positive control. In all experiments,
cells were cotransfected with 1 µg of the pSV
-galactosidase vector to normalize differences in transfection efficiency. Cells were
harvested 24 h after transfection and lysed in reporter lysis buffer (Promega). Luciferase assay reagent containing luciferyl-CoA was
added after centrifugation. Luciferase activity was determined in a
LUMAT LB9501 (Berthold). The
-galactosidase enzyme assay (Promega)
was used for the determination of
-galactosidase activity. Each
experiment was repeated three times with two distinct plasmid preparations, and measurements were done in triplicate. The impact of
transcription factor binding to consensus motifs within the core
promoter region was assessed using promoter reporter constructs containing mutated binding sites or truncated constructs. Mutated inserts of the
157 GC-box and
140 E-box sites were generated using
extended versions of the forward primer used for the amplification of
the
175/+224 reporter construct. Reporter constructs with mutated
91 GnC,
62 DR4, or
24 TATA motifs were generated following a
two-step cloning strategy. Two PCR fragments were generated that
overlap at the DNA motif of interest, replacing it by either a
SacI (
91 GnC) or an EcoRI restriction site. In
the case of the DR4 element, mutations introduced were identical to
those reported by Costet et al. (15) using a SpeI
restriction site in its vicinity. Overlapping fragments were ligated
after digestion with the corresponding restriction enzyme and
subsequently cloned into pGL3 basic vectors. The pPacSp1 and pPacSp3
expression vectors have been kindly provided by L. Lania (Naples, Italy).
5'-Rapid Amplification of cDNA Ends
(RACE)-PCR--
Extension of the ABCA1 5' region was achieved by
RACE-PCR with commercially available fetal liver cDNA libraries
(CLONTECH) ligated to adapter sequences as
template. Advantage cDNA polymerase (CLONTECH)
was employed for PCRs using primers derived from the published ABCA1
sequence (accession number AJ012376): A1(97)R, 5'-CATGTTGTTCATAGGGTGGGTAGC-3'; A1(69)R,
5'-CCGAACAGAGATCAGGATCAGGAA-3'. The specificity of resulting PCR
products was confirmed by nested PCR using the primer A1(33)R
5'-CCAGGCCACTTCCAGTAACAGC-3'.
Primer Extension Assay--
Reverse primers A1-PX1R
5'-AAAACAGAACCGGGGAAAAA-3', A1-PX2R 5'-GAGAACCGGCTCTGTTGGT-3',
complementary to sequences at position +151 and +112, respectively, of
the ABCA1 cDNA obtained by RACE-PCR were used for primer extension
analysis. Oligonucleotides were end-labeled with
[
-32P]ATP by T4 polynucleotide kinase
(Invitrogen) and subsequently purified with Sephadex G25 columns
(Roche Diagnostics). Fibroblast total RNA (10 µg) was annealed with
an excess of end-labeled primers at 58 °C for 1 h according to
the instructions of the manufacturer using the Promega primer extension
kit. Reverse transcription reaction was performed for 30 min at
42 °C with avian myeloblastosis virus reverse transcriptase. Samples
were analyzed on a 8% polyacrylamide gel containing 8 M
urea and audioradiographed with Eastman Kodak Co. BioMax MR films at
80 °C.
RNase Protection Assay--
DNA fragments were obtained by PCR
(High Fidelity PCR System; Roche Diagnostics) using A1-RP1
5'-CGTGCTTTCTGCTGAGTGAC-3' as forward primer in combination with
A1-PX1R and A1-PX2R (identical to those used for primer extension
assays) as reverse primers within exon 1 of the ABCA1 gene. The
resulting fragments were cloned into pCRII TOPO dual promoter vector
for the generation of riboprobes by in vitro transcription
and sequenced. T7 RNA polymerase-mediated in vitro
transcription of the linearized construct was performed in the presence
of [
-32P]CTP using the Riboprobe® Combination
System-SP6/T7 (Promega). Radiolabeled transcripts were treated with
DNase I and purified with Sephadex G50 columns (Roche Diagnostics).
Fibroblast total RNA (10 µg) was hybridized overnight at 50 °C
with the riboprobes. Finally, the samples were digested by RNase A and
RNase T1 using the RNase protection kit from Roche Diagnostics
according to the recommendations of the manufacturer. The samples were
analyzed on an 8% polyacrylamide gel containing 8 M urea
and audioradiographed with Kodak BioMax MR films at
80 °C.
Further, the plasmid containing the insert generated with primers
A1-RP1 and A1-PX1R was sequenced with [
-35S]ATP and
primer A1-PX1R using the T7 Sequenase kit (Amersham Biosciences)
according to the recommendations of the manufacturer and served as
sequencing ladder.
Cell Lines, Transfections, and Oncostatin M (OM)
Stimulation--
All cell lines were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA). RAW 264.7 macrophages, HepG2, Chinese hamster ovary, and HeLa cells were cultured in Dulbecco's modified Eagle's medium (Biowhittaker) supplemented with 10%
heat-inactivated fetal calf serum (Sigma). Cells were incubated in a
5% CO2 atmosphere at 37 °C. Drosophila S2
cells were grown at 23 °C in Schneider medium (Invitrogen)
supplemented with 10% heat-inactivated fetal calf serum and 1%
glutamine. RAW 264.7 macrophages, HepG2, Chinese hamster ovary, and
HeLa were transiently transfected co-transfected with pPacSp1 and
pPacSp3 expression vectors and different ABCA1 promoter constructs
using Fugene® reagent (Roche Diagnostics). 1,2-Dioleoyl-3-trimethylammonium propane transfection reagent (Roche
Diagnostics) was used for the transfection of Drosophila S2
cells. All transfection protocols were carried out according to the
recommendations of the manufacturers. For oncostatin M stimulation
experiments, 24 h after transfection with ABCA1 promoter constructs increasing amounts (0, 0.1, 1, and 10 nM) of OM
were added to the cells for different periods of time (2, 4, 8, and 24 h) before luciferase activity was determined.
Electrophoretic Mobility Shift Assays--
An equivalent of
40,000 cpm of double-stranded oligonucleotide probe containing the
desired promoter sequence was incubated either with 10 µg of nuclear
extract from RAW cells or 25 µg of nuclear extract from Chinese
hamster ovary cells transiently transfected with pPacSp1 and pPacSp3 as
described previously (22) in a buffer containing 50 mM
HEPES/HCl, pH 7.9, 6 mM MgCl2, 50 mM dithiothreitol, 100 µg/ml bovine serum albumin, 0.01%
Nonidet P-40, and 2 µg of poly(dI-dC) (Amersham Biosciences) at room
temperature for 20 min. Supershift analysis was carried out using 1 µl of antisera (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) against the indicated transcription factors. In competition
experiments, nuclear extracts were preincubated with a 100-fold molar
excess of competitor for 10 min prior to the addition of the
radiolabeled probe. In addition, nuclear extracts were incubated with
oligonucleotides containing mutated GC-box and E-box sites. A detailed
description of the oligonucleotides used in EMSA analysis is shown in
Fig. 5. DNA-protein complexes were resolved on a native 8%
polyacrylamide gel and audioradiographed with Kodak BioMax MR films at
80 °C.
Determination of ABCA1 mRNA Levels--
ABCA1 mRNA
expression was analyzed by a quantitative two-step RT-PCR assay
established in our laboratory using the Light Cycler technology (23).
Total RNA from HeLa cells was isolated with Trizol reagent (Sigma). RNA
concentration, purity, and integrity were assessed using the Agilent
2100 bioanalyzer and the RNA 6000 LabChip R kit (Agilent
Technologies). First-strand cDNA synthesis was performed using
avian myeloblastosis virus reverse transcriptase (Roche Diagnostics)
plus 10× reaction buffer, RNase inhibitor, deoxynucleotide mix (1 mM), random primer p(dN)6, MgCl2,
and 1 µg of total RNA. The following program was used: 25 °C for
10 min, 42 °C for 60 min, and 95 °C for 5 min. The FastStart DNA
Master Hybridization Probes Kit (Roche Diagnostics) was used with a
primer pair specific for the 205-bp ABCA1 fragment comprising base
pairs 1327-1532 of the coding sequence and two hybridization probes in
order to detect PCR product accumulation. For quantification, a
standard curve was generated with external homologous RNA after cloning of this fragment into the pCRII TOPO dual promoter vector and in
vitro transcription of the linearized construct by T7 RNA
polymerase. Results were controlled for the expression of the
housekeeping gene (porphobilinogene deaminase). Primers and
hybridization probes for porphobilinogene deaminase were obtained from
TIB Molbiol.
Efflux Experiments--
RAW 264.7 cells were transiently
transfected with increasing amounts of pPacSp1 or mock plasmid. Efflux
assays were performed with minor modifications as recently described
(5). RAW 264.7 cells were transiently transfected and cultured for
24 h. Subsequently, cells were radiolabeled with 1.5 µCi/ml
[14C]cholesterol and 10 µCi/ml
[3H]choline and loaded with 40 µg/ml enzymatically
modified LDL, which was prepared as described elsewhere (24). Cells
were incubated for 24 h in six-well plates containing Dulbecco's
modified Eagle's medium supplemented with 5% lipoprotein-deficient
serum and 10 µM 20(S)-OH-cholesterol, 10 µM 9-cis-retinoic acid (Sigma). Cells were
washed and chased for 17 h with either 100 µg/ml
HDL3 protein or 10 µg/ml purified ApoA-I (Sigma) or
medium alone. Lipids were extracted as previously described (25).
Radioactivity was determined by liquid scintillation counting. Lipid
efflux is expressed as the ratio of counts in medium to total counts.
Specific efflux was calculated by subtraction of efflux rates in the
presence of ApoA-I or HDL3 from those in the absence of
lipid acceptors.
 |
RESULTS AND DISCUSSION |
Mapping of the ABCA1 Transcription Initiation Site--
In order
to precisely map the position of the 5'-end of exon 1, an RNase
protection assay using genomic/cDNA hybrid clones encompassing 138 bp upstream of the sequence obtained by 5'-RACE-PCR (data not shown)
and either 151 or 112 bp of exon 1 was employed. As depicted in Fig.
1A, a single protected 161- or
122-bp fragment appeared, which was appropriate in size and consistent
with the results obtained by 5'-RACE-PCR. This finding was further
confirmed by primer extension analysis employing the same reverse
primer (A1-PX1R) within exon 1 used for RNase protection assays and RNA obtained from human fibroblasts. As shown in Fig. 1B, a
major transcript can be detected at a size corresponding to that
obtained by an RNase protection assay. The exact position of the
transcription initiation site, which also defines the ABCA1 promoter
region, is indicated in Fig. 2.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
The transcription initiation site of ABCA1 is
localized 25 bp downstream of the TATA box. A, RNase
protection assay. R1 and R2, riboprobes amplified
with forward primers A1-PX1R and A1-PX2R, respectively, in combination
with the reverse primer A1-RP1. Primers A1-PX1R and A1-PX2R
corresponded to positions +151 and +112, respectively, of the ABCA1
cDNA sequence obtained by RACE-PCR. Riboprobes were hybridized with
10 µg of total RNA isolated from human fibroblasts. A prominent
161-bp protected fragment was detected after overnight exposure with
riboprobe R1. A corresponding 122-bp sized protected fragment appeared
using riboprobe R2, which lacks 39 bp of exon 1 that were included in
R1. The exact localization of the transcription initiation site is
indicated by an arrow in the sequence shown at
the left. The TATA box at the top of the
sequence is localized 25 bp downstream of the identified
transcription start site. Lanes A, C,
G, and T show an
[ -35S]ATP-labeled sequencing ladder using a vector
insert identical to R1 and primer A1-PX1R. Lane depicts a
[ -32P]ATP-labeled X174 HinfI-digested
DNA marker. B, primer extension analysis. P1 shows a
[ -32P]ATP-labeled transcript obtained by annealing and
reverse transcription of 10 µg of fibroblast total RNA using primer
A1-PX1R. The resulting band corresponded in size to the 161-bp
protected R1 fragment obtained by RNase protection analysis.
Lane depicts a [ -32P]ATP-labeled
X174 HinfI-digested DNA marker.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 2.
Genomic sequence of 919 nucleotides preceding
exon 1 of the human ABCA1 gene. The boundary to intron 1 is
underlined. Intron sequence is shown in lowercase
letters. The transcription initiation site is indicated by
an arrow. Putative transcription factor binding sites are
boxed.
|
|
Identification of the Promoter Sequence Required for Basal
ABCA1 Expression--
The genomic region upstream of the transcription
initiation site of ABCA1 contains several putative elements that might
be responsible for transcriptional regulation (Fig. 2). In addition to
the recently described DR4 element mediating
oxysterol-dependent activation of the promoter (15, 16) and
the GnT motif binding the transcriptional repressor ZNF202 (21), a
canonical TATA box is located at position
24. Further upstream,
two GnC motifs (position
91 (GGGGCGGGG) and position
157
(GGGGCGGGCCC)) and an E-box (position
140, CACGTG) show high homology
to the corresponding region within the murine ABCA1 promoter. To
investigate the location of the basal promoter apparatus required for
the expression of ABCA1 in macrophages and liver cells, we performed
transient transfection experiments with reporter constructs containing
exon 1 and increasing portions of the ABCA1 promoter (Fig.
3). Vectors were transfected into RAW
264.7 and HepG2 cells. In both cell lines, the full-length promoter
sequence resulted in a more than 100-fold induction of luciferase
activity as compared with the promoterless construct. The construct
containing only exon 1 (positions +12/+224) displayed no significant
promoter activity. In contrast, a 24-fold increase was observed by
extending the 5'-end up to position
79, which includes the TATA box.
Promoter activity increased to 40-70-fold, employing the
175/+224
construct that includes an additional 187 bp upstream of the
transcription initiation site. Taken together, these data implicate
that the minimal sequence required for ABCA1 promoter activity in
RAW 246.7 and HepG2 cells is located in the region
175/+224.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
The ABCA1 core promoter contains two GC-rich
elements and an E-box. Putative regulatory elements and luciferase
activity analysis of pGL3 reporter gene vectors containing exon 1 and
successively truncated 5' regions of the ABCA1 gene are shown. RAW
macrophages (gray bars) and HepG2 cells
(open bars) were transfected with 2 µg of each
reporter gene construct and 1 µg of pSV -gal plasmid and cultured
for 24 h. A representative experiment is shown, which was
independently repeated three times. Luciferase activity was normalized
for -galactosidase activity and protein concentrations. Results are
expressed as -fold value of promoterless pGL3-basic vector and given as
mean ± S.D. of triplicate measurements.
|
|
The ABCA1 Core Promoter Is Regulated by a TATA box, Two GnC Sites,
and an E-box--
Due to the high homology to the murine ABCA1
promoter sequence, we investigated in detail the impact of the
24
TATA box, the
91 and
157 GnC motifs, and the
140 E-box. As shown
in Fig. 4, the exchange of the TATA box
by an EcoRI site almost completely abolished promoter
activity of the
79/+224 region, strongly suggesting a pivotal role of
this element for basal promoter induction. Mutations introduced in the
91 GnC motif within the
175/+224 reporter construct diminished
promoter activity more than 50% to a level comparable with the wild
type
79/+224 region. Considering the particular location of the Sp1
binding site relative to the transcription initiation site (Fig. 2) and
other reports on the interaction of Sp1 and TATA-binding protein or
TAF110 (26), Sp1 may play a critical role in the formation or
recruitment of the transcription initiation complex at the core
promoter. Thus, within the
175/+224 core promoter region, the TATA
box and the
91 GnC motif are pivotal elements for the basal
transcriptional activation of ABCA1. Interestingly, mutations of the
157 GnC motif and the
140 E-box both (Fig. 4) increased promoter
activity up to 2-fold, suggesting that these regions function as
transcriptional repressors.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
E-box and GnC motifs modulate ABCA1 core
promoter activity in RAW 264.7 cells. 1 × 106
RAW 264.7 cells were transfected with 1 µg of pSV -gal and 2 µg
of 175 ABCA1 pGL3 basic vector containing the wild type promoter
sequence ( 175/+224) or either mutated or truncated sequences as
indicated in the corresponding vector scheme and described under
"Experimental Procedures." Transfected cells were cultured for
24 h before they were assayed. A representative experiment is
shown, which was independently repeated three times. Luciferase
activity was normalized for -galactosidase activity and protein
concentrations. Results are expressed as -fold value of promoterless
pGL3-basic vector and given as mean ± S.D. of triplicate
measurements.
|
|
Transcription Factors Binding to the Proximal
175 bp ABCA1
Promoter--
To identify nuclear proteins interacting with the GnC
motifs and the E-box, EMSAs were performed using two probes spanning from
174 to
125 and from
114 to
65, respectively (Fig.
5A). The interaction of
fragment
174/
125, comprising an Sp1 site and an E-box, with RAW
nuclear extracts resulted in four specific protein-DNA complexes (Fig.
5B, lane 1). The specificity of
binding was shown by competition with unlabeled oligonucleotide, which eliminates these complexes completely (lane 7).
In order to identify the protein factors that form these complexes, we
used EMSA supershift experiments with antibodies specific for
transcription factors that are known to be able to bind to GC- and
E-boxes. No supershifted complexes were observed with antibodies
against AP-2, C/EBP
, Arnt1, Max1, SREBP1, SREBP2, E2F1, c-Myc,
RXR
, LXR
, HNF-3
, or HNF-4
(data not shown). In contrast,
antibodies specific for Sp1 and Sp3 resulted in supershifted complexes
(Fig. 5, lanes 2 and 3). The slowest
migrating complex was partially shifted by either antibody, suggesting
that this band represents a doublet of unresolved Sp1 and Sp3 bands.
The fastest migrating DNA-protein complex was completely shifted by
anti-Sp3 antibody, thus showing binding of Sp3 alone. These results
indicate that Sp1 and Sp3 are not co-bound on the same DNA molecule,
since anti-Sp3 antibody did not affect the formation of the
Sp1-specific complexes and anti-Sp1 antibody did not supershift the
Sp3-specific complexes. This suggests that Sp1 and Sp3 compete for the
binding to the region
174/
125 of the ABC1 promoter. Using
antibodies specific for HNF-1
, USF1, and USF2 (lanes
4-6), we could also show the abolition of the intermediate
band. However, only USF1 and USF2 antisera produce a supershift,
whereas anti-HNF-1 antibody seems to inhibit the formation of the
complex rather than produce a supershift. Since both USF1 and USF2
antibodies fully displaced the complex (lanes 5 and 6), we conclude that USF1/USF2 heterodimers are largely
predominant, whereas the amount of USF1 and USF2 homodimers is very
low, and they are only visible after long exposure of the
autoradiograph. In order to map the binding area in greater detail and
to show whether Sp1, Sp3, and USF1/2 bind to the Sp1 site and E-box,
respectively, mutations were created with nucleotide substitutions as
shown in Fig. 5A (upper line). All
specific complexes were displaced when using cold wild type competitor
(
174/
125) (lane 7). However, mutant M1
retains only the ability to displace the E-box complex (lane
8), whereas M2 competes for binding to the GnC motif
(lane 9). The double mutant M1/2 allows no
competition for nuclear protein binding. These data suggest that the
specific binding of Sp1, Sp3, and USF1/2 to region
175/
125
critically involves the GnC motif at position
157 and the E-box at
position
140. To determine whether the proximal promoter sequence,
including the Sp1 site at position
91 is bound by nuclear factors, we
performed additional EMSAs using a probe spanning from
114 to
65
(Fig. 5A, lanes 11-15). Incubation
with nuclear extracts from RAW cells resulted in the formation of three
specific complexes (lane 11). According to the
consensus binding sites for Sp1 and C/EBP
, we performed supershift
analysis using antibodies specific for C/EBP
or Sp3. This did not
result in a supershifted complex or complex reduction (data not shown
and lane 13), whereas the addition of anti-Sp1
polyclonal serum diminished the lowest migrating band and produced a
supershifted complex. To confirm the binding of Sp1 to its consensus
site, we created the mutated fragment M3 (Fig. 5A,
lower line) and used it for competition
experiments together with the wild type (
114/
65) probe in EMSAs. In
contrast to the cold wild type oligonucleotide, which has the ability
to displace all specific complexes (lane 14),
mutant M3 does not compete for binding of Sp1 (lane
15). These data show that the GnC motif in the proximal
promoter fragment (
114/
65) interacts with Sp1 but not with Sp3.

View larger version (102K):
[in this window]
[in a new window]
|
Fig. 5.
Sp1, Sp3, and USF factors binding to elements
in the ABCA1 core promoter. A, DNA sequences of wild
type and mutant oligonucleotides used in EMSA experiments are shown.
The Sp1 site and the E-box in probe ( 174/ 125) and the Sp1 site in
probe ( 114/ 65) are boxed. Base substitutions are
indicated by arrows under the
sequence. The mutants M1 and M2 destroy the Sp1-site and
E-box in 174/ 125, and the mutant M3 destroys the Sp1 site in
114/ 65. B, EMSA analysis was performed with end-labeled
oligonucleotides and 15 µg of RAW nuclear extract. 174/ 125 probe
was incubated with nuclear extract only (lane 1)
or with extracts preincubated with anti-Sp1 (lane
2), anti-Sp3 (lane 3), anti-HNF-1
(lane 4), anti-USF1 (lane
5), anti-USF2 (lane 6), or unlabeled
competitors (lanes 7-10). Lane
7 contains wild type competitor, lane
8 contains competitor with Sp1-site mutated (M1),
lane 9 competitor has the E-box mutated (M2), and
lane 10 contains competitor with both Sp1 and
E-box mutations (M1/2). Reactions in lanes 11-15
contain probe ( 114/ 67) with nuclear extracts alone (lane
11) or preincubated with anti-Sp1 (lane
12), anti-Sp3 (lane 13), or wild type
(lane 14) and M3 (lane 15)
competitor oligonucleotides. Supershifted complexes are marked with
brackets, and the free probe is marked with an
arrow. The asterisks denote nonspecific
interaction bands, which were not consistently seen with different
nuclear extract preparations. The bands marked with a cross
are specific low molecular weight complexes that have not been
identified.
|
|
Sp1-mediated ABCA1 Promoter Activation Can Be Repressed by Sp3 via
the
157 GnC Motif--
We further elucidated the role of Sp1 and Sp3
on ABCA1 transcription by employing Drosophila S2 cells that
lack endogenous Sp factors. Using the (
175/+224) reporter vector, we
observed a dose-dependent increase of promoter activity
after transfection with increasing amounts of pPacSp1 (Fig.
6A, left
panel), while no significant effect appeared with pPacSp3
alone (middle panel). Since there was evidence
from our EMSA analysis (Fig. 5) and luciferase assays (Fig. 4) that Sp3
competes with Sp1 for DNA binding and represses promoter activity, we
co-transfected Drosophila S2 cells with increasing amounts
of pPacSp3 in the presence of constant pPacSp1 levels. Among these
conditions, Sp3 was able to dose-dependently down-regulate
promoter activity toward basal levels (Fig. 6A, right panel). As a next step, we investigated the
role of both GnC motifs by co-transfecting Drosophila S2
cells with the (
175/+224) reporter vector containing either a mutated
91 or a
157 GnC motif or with the truncated (
79/+224) vector
lacking both sites (Fig. 6B). Cells were transfected either
with pPacSp1 (Fig. 6B, crossed bars)
or an excess of pPacSp3 in the presence of pPacSp1 (gray
bars) or mock (black bars). While no
significant Sp1/3 effect was seen, using the
79/+224 vector
mutation of the
91 GnC motif altered neither the induction by Sp1 nor
the Sp3-mediated repression. In contrast, mutation of the
157 GnC
motif abolished Sp3-mediated repression, whereas induction by Sp1 was
not influenced. These data implicate that (i) both GnC motifs are
capable of inducing ABCA1 expression and (ii) the
157 GnC box
mediates repression within the ABCA1 core promoter. In
accordance with the results from electrophoretic mobility shift assays
Sp1 and Sp3 seem to compete for DNA binding. Whereas Sp1 acts a potent
activator, Sp3 binds with high affinity to the
157 GnC box without
the ability to promote transcription. Thus, the Sp3-mediated repression
seems to be the result of occupying the Sp1 binding domain, which has been reported as a common mechanism of how members of the Sp family modulate transcriptional regulation (27).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
The transcriptional activation of ABCA1 by
Sp1 can be repressed by Sp3 via the 157 GC box in
Drosophila S2 cells. A, 3 × 106 S2 cells were transfected with 1 µg of pSV -gal, 2 µg of 175 ABCA1 pGL3 basic vector containing the wild type promoter
sequence ( 175/+224), and increasing amounts of either pPacSp1
(left panel) or pPacSp3 expression constructs.
Sp3 transfection was performed in the absence (middle
panel) or presence (right panel) of
Sp1. Results are given as -fold induction as compared with cells
co-transfected with 2 µg of 175 ABCA1 pGL3 and 3 µg of empty
expression vector. B, 3 × 106 S2 cells
were transfected with 1 µg of pSV -gal and 2 µg of 175 ABCA1
pGL3 basic vector containing the wild type promoter sequence
( 175/+224) or either mutated GC boxes as described under
"Experimental Procedures" or the 79 ABCA1 pGL3 basic vector.
Mutated sites are indicated by an X in the corresponding
vector scheme. Cells were co-transfected either with empty expression
vector (black bars), 1 µg of pPacSp1
(crossed bars), or 1 µg of pPacSp1 and 2 µg
of pPacSp3 expression vector (gray bars) and
incubated for 24 h. Results are given as -fold induction as
compared with cells co-transfected with 2 µg of 175 ABCA1 pGL3 and
3 µg of empty expression vector. A representative experiment is
shown, which was independently repeated three times. Luciferase
activity was normalized for -galactosidase activity and protein
concentrations. Results are expressed as -fold value of 175 wild type
ABCA1 pGL3-basic vector and given as mean ± S.D. of triplicate
measurements.
|
|
Cellular Lipid Efflux Rates Are Enhanced by Sp1-mediated Increase
of ABCA1 mRNA Expression--
In order to examine whether
Sp1-mediated transactivation is functionally relevant, we first
investigated ABCA1 mRNA expression in HeLa cells transiently
transfected with increasing amounts of either pPacSp1. We employed a
real time RT-PCR method based on the LightCycler technology using
external standards in order to quantitatively and specifically
determine ABCA1 mRNA levels. HeLa cells characteristically exhibit
a low constitutive ABCA1 expression, which is in the range of 0.3 pg/µg total RNA and about 200-fold less than in human macrophages
(data not shown). As shown in Fig.
7A, we observed a
dose-dependent up to 2.5-fold induction of ABCA1 mRNA
levels. To confirm that these transcriptional mechanisms are of
functional relevance for cellular lipid transport, we performed efflux
experiments with RAW 264.7 cells transiently transfected with Sp1.
Cells were radiolabeled with 1.5 µCi/ml
[14C]cholesterol and 10 µCi/ml
[3H]choline and loaded with 40 µg/ml enzymatically
modified LDL. Efflux was induced with either 100 µg/ml
HDL3 protein or 10 µg/ml purified apoA-I or medium alone.
Since specific cellular lipid efflux rates in RAW 264.7 cells highly
depend on the presence of retinoic acids, we performed these
experiments among continuous stimulation with 9-retinoic acid and 20-OH
cholesterol. Under these conditions, we observed a significant 2-fold
enhancement of apoA-I- and HDL3-mediated specific cellular
cholesterol and phospholipid efflux (Fig. 7B), which implies
that the Sp1-dependent transcriptional mechanism is
relevant in vivo. Also, Sp1 plays a critical role in the
regulated expression of proteins and enzymes involved in lipoprotein
metabolism during myeloid differentiation (22, 28) and therefore may
also contribute to the differentiation-dependent regulation
of ABCA1 observed in human monocytes and macrophages (6). There is
evidence that Sp1 mediates not only activity but also specificity and
inducibility during differentiation (29, 30). How Sp1 mediates this
specificity is not clear, but in one case Sp1 binds to its myeloid
target in vivo in myeloid cells only (29). Although Sp1 is
ubiquitous, which fits to the broad tissue expression pattern of ABCA1
(6), it is preferentially expressed in hematopoietic cells (31). Sp1 is
also capable of mediating responses to retinoic acid, thyroid hormone,
and retinoblastoma protein, all of which may influence myeloid
differentiation.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Sp1-mediated increase of ABCA1 mRNA
expression causes increased cellular lipid efflux rates.
A, 1 × 107 HeLa cells were transfected
with increasing amounts of pPacSp1 and inverse portions of empty
expression vector (mock). Total RNA was isolated after
48 h and reverse transcribed. ABCA1 mRNA expression was
quantified by LightCycler technology using an external ABCA1-specific
standard as described under "Experimental Procedures." Results were
normalized for porphobilinogen deaminase expression (PBGD)
and shown as ABCA1/porphobilinogene deaminase ratio. B,
2 × 105 RAW 264.7 cells were transiently transfected
with 2 µg of pPacSp1 (black bars) or empty
expression vector (mock, gray bars).
Cells were radiolabeled 24 h after transfection as described under
"Experimental Procedures." Cells were incubated in six-well plates
containing Dulbecco's modified Eagle's medium supplemented with 5%
lipoprotein-deficient serum and 10 µM
20(S)-OH-cholesterol, 10 µM
9-cis-retinoic acid (Sigma) and loaded with 40 µg/ml
enzymatically modified LDL for 24 h. Subsequently, cells were
washed and chased for 17 h either with 100 µg/ml
HDL3 protein or 10 µg/ml purified apoA-I or medium only.
Results are given as mean ± S.D. of specific efflux from
measurements of four wells. *, p < 0.05 comparing the
specific efflux of pPacSp1 and mock-transfected cells by t
test for independent samples.
|
|
Impact of GnC Motifs on Oxysterol-mediated ABCA1 Induction--
To
analyze whether the recently reported LXR/RXR-mediated induction of
ABCA1 (15, 16), which is transmitted by a nuclear hormone receptor
pathway, also involves Sp1-mediated transcription, we used different
mutated core promoter constructs lacking either the DR4 (LXR/RXR)
element in different combinations with mutated up- or downstream GnC
motifs (Fig. 8). A significant residual transcriptional induction of ABCA1 in the absence of the DR4 element, which was abolished by mutating the
91 GnC motif, provided evidence that in addition to the effect on macrophage differentiation, the
oxysterol-dependent pathway activating ABCA1 transcription depends also on functional GnC motifs. Nevertheless, putative binding
sites for other transcription factors involved in myeloid differentiation such as Evi-1 (32) or MZF-1 are present in the ABCA1 promoter region and may also be of importance.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
The DR4-dependent
oxysterol-mediated induction of ABCA1 is modulated by the 157 and
91 GC-box in HepG2 cells. HepG2 cells were transfected with 1 µg of pSV -gal and 2 µg of 175 ABCA1 pGL3 basic vector
containing the wild type promoter sequence ( 175/+224) or either
mutated GC box as described under "Experimental Procedures."
Mutated sites are indicated by an X in the corresponding
vector scheme. 4 h after transfection, cells were stimulated with
10 µM 20-OH(S)-cholesterol and 10 µM 9-cis-retinoic acid (9CRA)
dissolved in 0.2% (v/v) ethanol. Cells were harvested after 24 h.
A representative experiment is shown, which was independently repeated
three times. Luciferase activity was normalized for -galactosidase
activity and protein concentrations. Results are expressed as -fold
values of unstimulated reporter gene vectors and given as mean ± S.D. of triplicate measurements.
|
|
Sterol-independent Regulation of the ABCA1 Promoter via
OM--
Following the results described above and based on recent
reports proposing a critical role for macrophage-derived OM in linking the immune system with hepatic and macrophage lipid metabolism (33), we
tested whether the cytokine oncostatin M has an impact on the
regulation of the ABCA1 promoter in HepG2 cells. As shown in Fig.
9A, the transcriptional
activity of ABCA1 increases steadily with time and in a
dose-dependent manner following OM activation. Maximum
induction was observed after 24 h with 10 nM OM
(6-7-fold), and a significant increase in promoter activity could
already be detected after 4 h of 10 nM OM incubation
(4-fold) (Fig. 9A). To further narrow down the upstream
region involved in OM-induced ABCA1 activation, we performed the same
type of promoter assays with various 5' deletion constructs (Fig.
9B). A significant induction by OM could be detected with
all constructs down to
175 bp. Further shortening of the promoter to
position +12 resulted in a complete loss of basal activity as well as
the stimulatory capacity of OM. This implies that the OM-inducible
region lies within the first
175 bp of the proximal ABCA1 promoter.
To examine whether the above described GnC motifs and the E-box can
mediate or repress this transcriptional induction, respectively,
mutated luciferase constructs were analyzed in reporter gene assays
(data not shown). As a result, neither mutagenesis of both GC-boxes at
positions
157 and
91 nor exchange of the
140 E-box influences the
OM responsiveness of the ABCA1 regulatory region. In conclusion, our
data for the first time demonstrate a strong, sterol-independent induction of the ABCA1 gene in human HepG2 cells by the pleiotropic cytokine oncostatin M, which involves a currently unknown sequence element located in the
175/+224 bp core promoter. In this respect, it
is of special interest that the LDL receptor promoter is one of the
transcriptional targets of OM in primary hepatocytes and HepG2 cells.
This induction also occurs independent of intracellular cholesterol
levels (33-36) and involves a C/EBP binding site and a cyclic
AMP-responsive element (36). Since the proximal ABCA1 promoter region
contains neither a C/EBP site nor a cyclic AMP-responsive element
consensus sequence, we speculate that these factors are not involved in
ABCA1 gene induction. Another report (37) describing OM-stimulated
transcription of the human
2(I) collagen gene shows that the OM
inducibility of the
2(I) collagen promoter is located within the
core promoter and binds the transcription factors Sp1 and Sp3. Three
copies of the 12-bp Sp element confer OM responsiveness to the
heterologous thymidine kinase promoter, providing evidence that Sp1/Sp3
binding sites can mediate OM induction. However, although the basal
promoter activity in RAW 246.7 and HepG2 cells is critically dependent
on Sp1/Sp3 elements in the ABCA1 promoter, these binding sites do not
confer OM induction. A likely explanation for this finding may be
differences in the specific sequence composition surrounding the GnC
motifs and the resulting combination of transcriptional modulators,
which are quite different in the
2(I) collagen promoter.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 9.
The ABCA1 core promoter contains an
oncostatin M-responsive element. A, HepG2 cells were
transfected with 2 µg of the 919/+224 construct and 1 µg of
pSV -gal plasmid and cultured for 24 h. Thereafter, the cells
were incubated with different concentrations (0.1, 1, and 10 nM) of oncostatin M for various time points (2, 4, 8, and
24 h) before measuring luciferase activity. A representative
experiment is shown, which was independently repeated three times.
Luciferase activity was normalized for -galactosidase activity and
protein concentrations. Results are expressed as -fold value of
unstimulated construct and given as mean ± S.D. of triplicate
measurements. B, HepG2 cells were transfected with 2 µg of
the indicated promoter constructs and 1 µg of pSV -gal plasmid and
cultured for 24 h. Thereafter, the cells were incubated with 10 nM oncostatin M for 4 h before measuring luciferase
activity. A representative experiment is shown, which was independently
repeated three times. Luciferase activity was normalized for
-galactosidase activity and protein concentrations. Results are
expressed as -fold value of promoterless pGL3-basic vector and given as
mean ± S.D. of triplicate measurements.
|
|
Although not involved in OM induction, the
140 E-box (CACGTG)
positioned between both GC-boxes in the core promoter region negatively
regulates ABCA1 expression via basic helix-loop-helix transcription
factors. We have identified binding of USF1, USF2, and HNF-1
by
screening transcription factors that are known to bind to E-boxes. USF1
and USF2 are the major basic helix-loop-helix transcription factors in
liver nuclear extracts (38). USF1/2 forms heterodimers on the ABCA1
promoter (Fig. 5), since both elements supershifted using either
antibodies against USF1 or USF2. In vivo, USF1/2
heterodimers represent over 66% of the USF binding activity, whereas
USF1 and USF2 homodimers represent less than 10%, which strongly
suggests a preferential association of heterodimers in vivo
(39). Interestingly, USF proteins, while being ubiquitously expressed,
are involved in the expression of several tissue-specific or
developmentally regulated genes (40). The HNF-4-regulated factor
HNF-1
has been described as a homeodomain-type transcription factor,
which plays an essential role during liver organogenesis by
transactivating a large number of hepatic genes (41). Maturity onset
diabetes of the young, type III (MODY3) is caused by mutation in the
HNF-1
gene (42). HNF-1
is further involved in the transcription
of several apolipoprotein genes and lipid transfer proteins, such as
apoB (43), the microsomal triglyceride transfer protein (44), apo(a)
(45), and apoIV (46). Interestingly, in healthy Canadian Oji-Cree
subjects, the HNF-1
G319S genotype variant was significantly
associated with higher plasma concentrations of high density
lipoprotein cholesterol and apoA-I (47). Since apoA-I and apoA-IV play
a pivotal role in the formation of HDL particles and regulation of HDL
pool size, similarities can be expected in the transcriptional regulation of these proteins and ABCA1-mediated cholesterol efflux.
 |
ACKNOWLEDGEMENTS |
We thank Professor Luigi Lania for kindly
providing pPacSp1 and pPacSp3 expression vectors and Daniel G. Tenen
for critical reading of the manuscript.
 |
FOOTNOTES |
*
This work was supported in part by Bayer AG Grant PO
708/1-1 and Deutsche Forschungsgemeinschaft Grant LA1203/2-1.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AJ252201.
These two authors contributed equally to this work.
¶
To whom correspondence should be addressed:
Universitätsklinikum Regensburg, Institut für Klinische
Chemie und Blutbank, Franz-Josef-Strau
-Allee 11, 93042 Regensburg, Germany. Tel.: 49-941944-6201; Fax: 49-941-944-6202;
E-mail: gerd.schmitz@klinik.uni-regensburg.de.
Published, JBC Papers in Press, February 11, 2002, DOI 10.1074/jbc.M110270200
 |
ABBREVIATIONS |
The abbreviations used are:
ABCA1, ATP-binding
cassette transporter A1;
HDL, high density lipoprotein;
LXR, liver X
receptor;
RXR, retinoid X receptor;
DR4, direct repeat separated by
four nucleotides;
USF, upstream stimulatory factor;
HNF, hepatic
nuclear factor;
apoA-I, apolipoprotein A-I;
C/EBP, CCAAT
enhancer-binding protein;
OM, oncostatin M;
RACE, rapid amplification
of cDNA ends;
LDL, low density lipoprotein;
EMSA, electrophoretic
mobility shift assay.
 |
REFERENCES |
| 1.
|
Bodzioch, M.,
Orso, E.,
Klucken, J.,
Langmann, T.,
Bottcher, A.,
Diederich, W.,
Drobnik, W.,
Barlage, S.,
Buchler, C.,
Porsch, O. M.,
Kaminski, W. E.,
Hahmann, H. W.,
Oette, K.,
Rothe, G.,
Aslanidis, C.,
Lackner, K. J.,
and Schmitz, G.
(1999)
Nat. Genet.
22,
347-351[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Brooks-Wilson, A.,
Marcil, M.,
Clee, S. M.,
Zhang, L. H.,
Roomp, K.,
van-Dam, M., Yu, L.,
Brewer, C.,
Collins, J. A.,
Molhuizen, H. O.,
Loubser, O.,
Ouelette, B. F.,
Fichter, K.,
Ashbourne, E. K.,
Sensen, C. W.,
Scherer, S.,
Mott, S.,
Denis, M.,
Martindale, D.,
Frohlich, J.,
Morgan, K.,
Koop, B.,
Pimstone, S.,
Kastelein, J. J.,
Hayden, M. R.,
et al..
(1999)
Nat. Genet.
22,
336-345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Rust, S.,
Rosier, M.,
Funke, H.,
Real, J.,
Amoura, Z.,
Piette, J. C.,
Deleuze, J. F.,
Brewer, H. B.,
Duverger, N.,
Denefle, P.,
and Assmann, G.
(1999)
Nat. Genet.
22,
352-355[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Assman, G.,
Schmitz, G.,
and Brewer-HB, J.
(1989)
in
The Metabolic Base of Inherited Disease
(Scriver, C. R.
, Beaudet, A. S.
, Sly, W. S.
, and Valle, D., eds)
, McGraw-Hill Book Co., New York
|
| 5.
|
Orso, E.,
Broccardo, C.,
Bottcher, A.,
Liebisch, G.,
Drobnik, W.,
Kaminski, W. E.,
Chen, H. M.,
Chambenoit, O.,
Götz, A.,
Diederich, W.,
Spruss, T.,
Luciani, M. F.,
Rothe, G.,
Lackner, K. J.,
Chimini, G.,
and Schmitz, G.
(2000)
Nat. Genet.
24,
192-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Langmann, T.,
Klucken, J.,
Reil, M.,
Liebisch, G.,
Luciani, M. F.,
Chimini, G.,
Kaminski, W. E.,
and Schmitz, G.
(1999)
Biochem. Biophys. Res. Commun.
257,
29-33[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Oram, J. F.,
Lawn, R. M.,
Garvin, M. R.,
and Wade, D. P.
(2000)
J. Biol. Chem.
275,
34508-34511[Abstract/Free Full Text]
|
| 8.
|
Lawn, R. M.,
Wade, D. P.,
Garvin, M. R.,
Wang, X.,
Schwartz, K.,
Porter, J. G.,
Seilhamer, J. J.,
Vaughan, A. M.,
and Oram, J. F.
(1999)
J. Clin. Invest.
104,
R25-R31
|
| 9.
|
Chawla, A.,
Boisvert, W. A.,
Lee, C. H.,
Laffitte, B. A.,
Barak, Y.,
Joseph, S. B.,
Liao, D.,
Nagy, L.,
Edwards, P. A.,
Curtiss, L. K.,
Evans, R. M.,
and Tontonoz, P.
(2001)
Mol. Cell
7,
161-171[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Chinetti, G.,
Lestavel, S.,
Bocher, V.,
Remaley, A. T.,
Neve, B.,
Torra, I. P.,
Teissier, E.,
Minnich, A.,
Jaye, M.,
Duverger, N.,
Brewer, H. B.,
Fruchart, J. C.,
Clavey, V.,
and Staels, B.
(2001)
Nat. Med.
7,
53-58[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Remaley, A. T.,
Rust, S.,
Rosier, M.,
Knapper, C.,
Naudin, L.,
Broccardo, C.,
Peterson, K. M.,
Koch, C.,
Arnould, I.,
Prades, C.,
Duverger, N.,
Funke, H.,
Assman, G.,
Dinger, M.,
Dean, M.,
Chimini, G.,
Santamarina, F. S.,
Fredrickson, D. S.,
Denefle, P.,
and Brewer, H. B., Jr.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12685-12690[Abstract/Free Full Text]
|
| 12.
|
Santamarina-Fojo, S.,
Peterson, K.,
Knapper, C.,
Qiu, Y.,
Freeman, L.,
Cheng, J. F.,
Osorio, J.,
Remaley, A.,
Yang, X. P.,
Haudenschild, C.,
Prades, C.,
Chimini, G.,
Blackmon, E.,
Francois, T.,
Duverger, N.,
Rubin, E. M.,
Rosier, M.,
Denefle, P.,
Fredrickson, D. S.,
and Brewer, H. B., Jr.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
7987-7992[Abstract/Free Full Text]
|
| 13.
|
Schmitz, G.,
and Langmann, T.
(2001)
Curr. Opin. Lipidol.
12,
129-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Santamarina-Fojo, S.,
Remaley, A. T.,
Neufeld, E. B.,
and Brewer, H. B., Jr.
(2001)
J. Lipid Res.
42,
1339-1345[Abstract/Free Full Text]
|
| 15.
|
Costet, P.,
Luo, Y.,
Wang, N.,
and Tall, A. R.
(2000)
J. Biol. Chem.
275,
28240-28245[Abstract/Free Full Text]
|
| 16.
|
Schwartz, K.,
Lawn, R. M.,
and Wade, D. P.
(2000)
Biochem. Biophys. Res. Commun.
274,
794-802[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Cavelier, L. B.,
Qiu, Y.,
Bielicki, J. K.,
Afzal, V.,
Cheng, J. F.,
and Rubin, E. M.
(2001)
J. Biol. Chem.
276,
18046-18051[Abstract/Free Full Text]
|
| 18.
|
Qiu, Y.,
Cavelier, L.,
Chiu, S.,
Yang, X.,
Rubin, E.,
and Cheng, J. F.
(2001)
Genomics
73,
66-76[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Vaisman, B. L.,
Lambert, G.,
Amar, M.,
Joyce, C.,
Ito, T.,
Shamburek, R. D.,
Cain, W. J.,
Fruchart-Najib, J.,
Neufeld, E. D.,
Remaley, A. T.,
Brewer, H. B., Jr.,
and Santamarina-Fojo, S.
(2001)
J. Clin. Invest.
108,
303-309[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Fu, X.,
Menke, J. G.,
Chen, Y.,
Zhou, G.,
MacNaul, K. L.,
Wright, S. D.,
Sparrow, C. P.,
and Lund, E. G.
(2001)
J. Biol. Chem.
276,
38378-38387[Abstract/Free Full Text]
|
| 21.
|
Porsch-Ozcurumez, M.,
Langmann, T.,
Heimerl, S.,
Borsukova, H.,
Kaminski, W. E.,
Drobnik, W.,
Honer, C.,
Schumacher, C.,
and Schmitz, G.
(2001)
J. Biol. Chem.
276,
12427-12433[Abstract/Free Full Text]
|
| 22.
|
Langmann, T.,
Buechler, C.,
Ries, S.,
Schaeffler, A.,
Aslanidis, C.,
Schuierer, M.,
Weiler, M.,
Sandhoff, K.,
de-Jong, P. J.,
and Schmitz, G.
(1999)
J. Lipid Res.
40,
870-880[Abstract/Free Full Text]
|
| 23.
|
Kielar, D.,
Dietmeier, W.,
Langmann, T.,
Aslanidisis, C.,
Probst, M.,
Naruszewicz, M.,
and Schmitz, G.
(2001)
Clin. Chem.
47,
2089-2097[Abstract/Free Full Text]
|
| 24.
|
Bhakdi, S.,
Dorweiler, B.,
Kirchmann, R.,
Torzewski, J.,
Weise, E.,
Tranum, J. J.,
Walev, I.,
and Wieland, E.
(1995)
J. Exp. Med.
182,
1959-1971[Abstract/Free Full Text]
|
| 25.
|
Rogler, G.,
Trumbach, B.,
Klima, B.,
Lackner, K. J.,
and Schmitz, G.
(1995)
Arterioscler. Thromb. Vasc. Biol.
15,
683-690[Abstract/Free Full Text]
|
| 26.
|
Chen, J. L.,
Attardi, L. D.,
Verrijzer, C. P.,
Yokomori, K.,
and Tjian, R.
(1994)
Cell
79,
93-105[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Kwon, H. S.,
Kim, M. S.,
Edenberg, H. J.,
and Hur, M. W.
(1999)
J. Biol. Chem.
274,
20-28[Abstract/Free Full Text]
|
| 28.
|
Tenen, D. G.,
Hromas, R.,
Licht, J. D.,
and Zhang, D. E.
(1997)
Blood
90,
489-519[Free Full Text]
|
| 29.
|
Chen, H. M.,
Pahl, H. L.,
Scheibe, R. J.,
Zhang, D. E.,
and Tenen, D. G.
(1993)
J. Biol. Chem.
268,
8230-8239[Abstract/Free Full Text]
|
| 30.
|
Zhang, D. E.,
Hetherington, C. J.,
Tan, S.,
Dziennis, S. E.,
Gonzalez, D. A.,
Chen, H. M.,
and Tenen, D. G.
(1994)
J. Biol. Chem.
269,
11425-11434[Abstract/Free Full Text]
|
| 31.
|
Saffer, J. D.,
Jackson, S. P.,
and Annarella, M. B.
(1991)
Mol. Cell. Biol.
11,
2189-2199[Abstract/Free Full Text]
|
| 32.
|
Hirai, H.
(1999)
Int. J. Biochem. Cell Biol.
31,
1367-1371[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Grove, R. I.,
Mazzucco, C.,
Allegretto, N.,
Kiener, P. A.,
Spitalny, G.,
Radka, S. F.,
Shoyab, M.,
Antonaccio, M.,
and Warr, G. A.
(1991)
J. Lipid Res.
32,
1889-1897[Abstract]
|
| 34.
|
Liu, J.,
Zhang, Y. L.,
Spence, M. J.,
Vestal, R. E.,
Wallace, P. M.,
and Grass, D. S.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
2948-2954[Abstract/Free Full Text]
|
| 35.
|
Liu, J.,
Streiff, R.,
Zhang, Y. L.,
Vestal, R. E.,
Spence, M. J.,
and Briggs, M. R.
(1997)
J. Lipid Res.
38,
2035-2048[Abstract]
|
| 36.
|
Liu, J.,
Ahlborn, T. E.,
Briggs, M. R.,
and Kraemer, F. B.
(2000)
J. Biol. Chem.
275,
5214-5221< |